Favorable outcome of extended treatment with adding pegylated Interferonα-2a to entecavir for HBeAg-positive chronic hepatitis B: a case report.

Hepatitis B virus (HBV) surface antigen (HBsAg) to anti-HBsAg (anti-HBs) seroconversion is the best and final objective of all available chronic hepatitis B (CHB) therapies. Unfortunately, this goal is not commonly obtained with current therapeutic approaches. Here, we reported a case that a Chinese CHB patient successfully achieved HBsAg seroconversion under extended individualized therapeutic schedule. At 48 weeks after entecavir (ETV) monotherapy, pegylated interferon alpha-2a (PEG-IFN-α-2a) was added, and the titers of HBsAg decreased and HBsAg loss was achieved. After 96 weeks of combination therapy, PEG-IFN-α-2a was stopped and ETV monotherapy was continued for additional 24 weeks. HBsAg seroconversion was sustained, 48 weeks after the end of all treatment.